Document:

Exhibit 4.5

   

   

  THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR
    THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR, IN THE OPINION OF
    LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

   

  WARRANT TO PURCHASE STOCK

   

  		Company:	CASTLE BIOSCIENCES, INC.
	 	Number of Shares:	[______] shares, plus all Additional Shares which Holder is entitled to purchase pursuant to Section 1.7
	 	Type/Series of Stock: 	Series F Preferred
	 	Warrant Price: 	$[______] per share
	 	Issue Date: 	[______________]
	 	Expiration Date:	[______________]                  See also Section 5.1(b).
	 	 	 
	 	Credit Facility:	This Warrant to Purchase Stock (“Warrant”) is issued in connection with that certain Amended and Restated Loan and Security Agreement of even date herewith between [_____________] and the Company (the “Loan

              Agreement”).

   

   

   

  THIS WARRANT CERTIFIES THAT, for good and valuable consideration, [________________] (together with any successor or permitted assignee or
    transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock (the “Class”)

    of the above-named company (the “Company”) at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this
    Warrant. Reference is made to Section 5.4 of this Warrant whereby [_____________] shall transfer this Warrant to its parent company, [_____________].

   

  Section 1  EXERCISE.

   

  1.1       Method of Exercise.  Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to
    the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a
    check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased.

   

  1.2       Cashless Exercise.  On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified
    in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall
    issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula:

   

  
    1.

    
      
 

  

  X = Y(A-B)/A

   

  where:

   

  		X =	the number of Shares to be issued to the Holder;

   

  		Y =	the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);

   

  		A =	the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

   

  		B =	the Warrant Price.

   

  1.3       Fair Market Value. If the Company’s common stock is then traded or quoted on a nationally recognized securities exchange,
    inter-dealer quotation system or over-the-counter market (a “Trading Market”) and the Class is common stock, the fair market value of a Share shall be the closing price or last sale price of a share of common stock reported for the
    Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s common stock is then traded in a Trading Market and the Class is a series of the Company’s convertible
    preferred stock, the fair market value of a Share shall be the closing price or last sale price of a share of the Company’s common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its
    Notice of Exercise to the Company multiplied by the number of shares of the Company’s common stock into which a Share is then convertible. If the Company’s common stock is not traded in a Trading Market, the Board of Directors of the Company shall
    determine the fair market value of a Share in its reasonable good faith judgment.

   

  1.4       Delivery of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the manner set forth in
    Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the
    Shares not so acquired.

   

  1.5       Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or
    mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the
    Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount.

   

  1.6       Treatment of Warrant Upon Acquisition of Company.

   

  (a)       Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related
    transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with another person or entity (other than a merger or
    consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own less
    than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization; or (iii) any sale or other transfer by the stockholders of the Company of shares
    representing at least a majority of the Company’s then-total outstanding combined voting power.

   

  
    2.

    
      
 

  

   

  (b)       Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the Company’s
    stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), and the fair market value of one Share as determined in accordance with Section 1.3
    above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder has not exercised this Warrant pursuant to Section 1.1 above as to all Shares, then this Warrant shall automatically be
    deemed to be Cashless Exercised pursuant to Section 1.2 above as to all Shares effective immediately prior to and contingent upon the consummation of a Cash/Public Acquisition. In connection with such Cashless Exercise, Holder shall be deemed to have
    restated each of the representations and warranties in Section 4 of the Warrant as of the date thereof and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon exercise. In the event of a
    Cash/Public Acquisition where the fair market value of one Share as determined in accordance with Section 1.3 above would be less than the Warrant Price in effect immediately prior to such Cash/Public Acquisition, then this Warrant will expire
    immediately prior to the consummation of such Cash/Public Acquisition.

   

  (c)       Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor entity
    shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if
    such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this Warrant.

   

  (d)       As used in this Warrant, “Marketable Securities” means securities meeting all of the following requirements: (i) the
    issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other
    information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing
    thereof is then traded in Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder in such
    Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y)
    does not extend beyond six (6) months from the closing of such Acquisition.

   

  1.7       Additional Shares. Upon the funding of each Supplemental Growth Capital Advance (as defined in the Loan Agreement) under the
    Second Tranche (as defined in the Loan Agreement), the Company shall be deemed to have automatically granted to Holder, in addition to the number of Shares which this Warrant can otherwise be exercised for by Holder, the right to purchase a number of
    additional Shares equal to one and one-quarter of one percent (1.25%) of the amount of such Supplemental Growth Capital Advance divided by the Warrant Price (collectively, such additional shares being called the “Additional Shares”).

   

  
    3.

    
      
 

  

  Section 2  ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

   

  2.1       Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Class
    payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which
    Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the
    number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser
    number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.

   

  2.2       Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Class are
    reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and
    series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant.
    The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations, substitutions, replacements or other similar events.

   

  2.3       Conversion of Preferred Stock. If the Class is a class and series of the Company’s convertible preferred stock, in the event that
    all outstanding shares of the Class are converted, automatically or by action of the holders thereof, into common stock pursuant to the provisions of the Company’s Certificate of Incorporation, including, without limitation, in connection with the
    Company’s initial, underwritten public offering and sale of its common stock pursuant to an effective registration statement under the Act (the “IPO”), then from and after the date on which all outstanding shares of the Class have been so
    converted, this Warrant shall be exercisable for such number of shares of common stock into which the Shares would have been converted had the Shares been outstanding on the date of such conversion, and the Warrant Price shall equal the Warrant Price
    in effect as of immediately prior to such conversion divided by the number of shares of common stock into which one Share would have been converted, all subject to further adjustment thereafter from time to time in accordance with the provisions of
    this Warrant.

   

  2.4       Adjustments for Diluting Issuances. Without duplication of any adjustment otherwise provided for in this Section 2, the number of
    shares of common stock issuable upon conversion of the Shares shall be subject to anti-dilution adjustment from time to time in the manner set forth in the Company’s Certificate of Incorporation as if the Shares were issued and outstanding on and as of
    the date of any such required adjustment.

   

  2.5       No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued
    shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the
    fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price.

   

  
    4.

    
      
 

  

  2.6       Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company, at
    the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from
    Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such adjustment.

   

  Section 3  REPRESENTATIONS AND COVENANTS OF THE COMPANY.

   

  3.1       Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:

   

  (a)       The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of the
    Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least $500,000 of such shares were sold.

   

  (b)       All Shares which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion of the Shares,
    shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws. The Company
    covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the Class, common stock and other securities as will be sufficient to permit the exercise in full of
    this Warrant and the conversion of the Shares into common stock or such other securities.

   

  (c)       The Company’s capitalization table as of the Issue Date is attached hereto as Schedule 1 and is true and complete, in all material
    respects, as of the Issue Date.

   

  3.2       Notice of Certain Events. If the Company proposes at any time to:

   

  (a)       declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in cash, property, stock, or
    other securities and whether or not a regular cash dividend;

   

  (b)       offer for subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or
    series of the Company’s stock (other than pursuant to contractual pre-emptive rights);

   

  (c)       effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the
    Class;

   

  (d)       effect an Acquisition or to liquidate, dissolve or wind up; or

   

  
    5.

    
      
 

  

  (e)       effect an IPO;

   

  then, in connection with each such event, the Company shall give Holder:

   

  (1)       at least seven (7) Business Days prior written notice of the date on which a record will be taken for such dividend,
    distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above;

   

  (2)       in the case of the matters referred to in (c) and (d) above at least seven (7) Business Days prior written notice of the date
    when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to exchange their shares for the securities or other property deliverable upon the occurrence of such event and such
    reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such event giving rise to the notice); and

   

  (3)       with respect to the IPO, at least seven (7) Business Days prior written notice of the date on which the Company proposes to
    file its registration statement in connection therewith.

   

  Company will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting or
    reporting requirements.

   

  Section 4  REPRESENTATIONS, WARRANTIES OF THE HOLDER.

   

  The Holder represents and warrants to the Company as follows:

   

  4.1       Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder, and any shares
    of common stock to be issued upon conversion of any such securities, are being acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also
    represents that it has not been formed for the specific purpose of acquiring this Warrant or the Shares.

   

  4.2       Disclosure of Information. Holder is aware of the Company’s business affairs and financial condition and has received or has had
    full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and
    receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without
    unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.

   

  4.3       Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
    risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and
    experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and
    certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons.

   

  
    6.

    
      
 

  

  4.4       Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.

   

  4.5       The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the Act
    in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise
    hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions
    of Rule 144 promulgated under the Act.

   

  4.6       Market Stand-off Agreement. The Holder agrees that the Shares shall be subject to the Market Stand-Off provisions in Section 2.10
    of the Company’s Fourth Amended and Restated Investors’ Rights Agreement and any similar provision of any successor agreement, as if the Holder were a party thereto for the purposes of such section.

   

  4.7       No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights or any other rights as a stockholder of
    the Company (except to the extent provided herein) until the exercise of this Warrant.

   

  Section 5  MISCELLANEOUS.

   

  5.1       Term and Automatic Conversion Upon Expiration.

   

  (a)       Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from time
    to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter.

   

  (b)       Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share
    (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised
    pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities)
    issued upon such exercise to Holder.

   

  5.2       Legends. The Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be
    imprinted with a legend in substantially the following form:

   

  THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE
    SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO [_____________] DATED [_________________], MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED
    UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

   

  
    7.

    
      
 

  

  5.3       Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the
    securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee
    (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel
    if the transfer is to [_____________] ([_____________]’s parent company) or any other affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act. Additionally, the Company
    shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act.

   

  5.4       Transfer Procedure. After receipt by [_____________] of the executed Warrant, [_____________] will transfer all of this Warrant
    to its parent company, [_____________]. By its acceptance of this Warrant, [_____________] hereby makes to the Company each of the representations and warranties set forth in Section 4 hereof and agrees to be bound by all of the terms and conditions of
    this Warrant as if the original Holder hereof. Subject to the provisions of Section 5.3 and upon providing the Company with written notice, [_____________] and any subsequent Holder may transfer all or part of this Warrant or the Shares issuable upon
    exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection with any such transfer, [_____________] or any subsequent Holder will give the
    Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if
    applicable); and provided further, that any subsequent transferee other than [_____________] shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant. Notwithstanding any contrary provision herein, at all
    times prior to the IPO, Holder may not, without the Company’s prior written consent, transfer this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, or any shares or other securities issued upon any conversion of any Shares
    issued upon any exercise hereof, to any person or entity who or that directly competes with the Company, except in connection with an Acquisition of the Company by such a direct competitor.

   

  5.5       Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered
    and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is
    confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may
    be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a
    transfer or otherwise:

   

  ______________________

   

  Attn:__________________

   

  ______________________

   

  ______________________

   

  Telephone:_____________

   

  Facsimile:_____________

   

  Email address:__________

   

  
    8.

    
      
 

  

  Notice to the Company shall be addressed as follows until Holder receives notice of a change in address:

   

  Castle Biosciences, Inc.

   

  Attn: Derek Maetzold

   

  2014 San Miguel Drive

   

  Friendswood, TX 77546

   

  5.6       Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
    instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought.

   

  5.7       Attorney’s Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party
    prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.

   

  5.8       Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall
    constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.

   

  5.9       Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without
    giving effect to its principles regarding conflicts of law.

   

  5.10       Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of
    any provision of this Warrant.

   

  5.11       Business Days. “Business Day” is any day that is not a Saturday, Sunday or a day on which [_____________] is
    closed.

   

  [Remainder of page left blank intentionally]

   

  [Signature page follows]

   

   

  
    9.

    
      
 

  

  
  IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives effective as
    of the Issue Date written above.

   

  “COMPANY”

   

  CASTLE BIOSCIENCES, INC.

   

  	By:	 	 
	 	 	 
	Name: 	 	 
	 	 	(Print)	 
	Title: 	 	 

   

  “HOLDER”

   

  [______________________]

   

  	By:	 	 
	 	 	 
	Name:	 	 
	 	 	(Print)	 
	Title: 	 	 

   

   

   

  
    
      
 

  

  
  APPENDIX 1

   

  NOTICE OF EXERCISE

   

  1.             The undersigned Holder hereby exercises its right purchase ________ shares of the Common/Series _______ Preferred [circle one]
    Stock of CASTLE BIOSCIENCES, INC. (the “Company”) in accordance with the attached Warrant To Purchase Stock, and tenders payment of the aggregate Warrant Price for such shares as follows:

   

  		[ ]	Check in the amount of $ payable to the order of the Company enclosed herewith

   

  		[ ]	Wire transfer of immediately available funds to the Company’s account

   

  		[ ]	Cashless Exercise pursuant to Section 1.2 of the Warrant

   

  		[ ]	Other [Describe]	 

   

  2.             Please issue a certificate or certificates representing the Shares in the name specified below:

   

  	 	 	 
	 	 	Holder’s Name	 
	 	
           

           

        	 
	 	
           

           

        	 
	 	 	(Address)	 

   

   

   

  3.             By its execution below and for the benefit of the Company, Holder hereby restates each of the representations
    and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof.

   

  	 	HOLDER:
	 	 	 
	 	 	 
	 	 	 
	 	By:	 
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 
	 	 	 
	 	(Date):	 

   

   

   

  
    Appendix 1

    
      
 

  

  
  SCHEDULE 1

   

  Company Capitalization Table

   

  See attached

    

   Schedule 1Exhibit 4.6

  

  

  THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL
    REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

  

  

  WARRANT TO PURCHASE STOCK

  

  

  	
          Company:

        	
          CASTLE BIOSCIENCES, INC., a Delaware corporation

        
	
          Number of Shares:

        	
          [______] (Subject to Section 1.7)

        
	
          Type/Series of Stock:

        	
          Series F Preferred (Subject to Section 1.7)

        
	
          Warrant Price:

        	
          $[_____] per share (Subject to Section 1.7)

        
	
          Issue Date:

        	
          [_________________]

        
	
          Expiration Date:

        	
          [_________________]. See also Section 5.1(b).

        
	
          Credit Facility:

        	
          This Warrant to Purchase Stock (as modified, amended and/or restated from time to time, the “Warrant”) is issued in connection with that certain Loan and Security Agreement of even date herewith among [__________], as Lender and Collateral Agent, the Lenders from time to time party
            thereto, including [__________], and the Company (as modified, amended and/or restated from time to time, the “Loan Agreement”).

        

  

  

  THIS WARRANT CERTIFIES THAT, for good and valuable consideration, [__________] [“[_____]” and,]  (together with any successor or permitted
    assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully
    paid and non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock (the “Class”) of the above-named company (the “Company”) at the above-stated
    Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. [Reference is made to Section 5.4 of this Warrant whereby [__________]
    shall transfer this Warrant to its parent company, [______________]].

  

  

  SECTION 1.      EXERCISE.

  

  

  

  1.1          Method of Exercise.  Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the Company the original of
      this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a check, wire transfer of
      same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased.

  

  

  1.2          Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above, but
      otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such
      number of fully paid and non-assessable Shares as are computed using the following formula:

  

  

    X = Y(A-B)/A

  

  

  where:

  

  

  
    		X =	
            the number of Shares to be issued to the Holder;

            

            

          

  

  
    		Y =	
            the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the
              aggregate Warrant Price);

          

  

  
    
      1

      
        
 

    

    
      	 	
              A=

            	
              the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

            

    

    

    

  

  
    		B =	
            the Warrant Price.

          

  

  

  

  1.3          Fair Market Value.  If the Company’s common stock is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or
      over-the-counter market (a “Trading Market”) and the Class is common stock, the fair market value of a Share shall be the closing price or
      last sale price of a share of common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s common stock is then traded in a Trading
      Market and the Class is a series of the Company’s convertible preferred stock, the fair market value of a Share shall be the closing price or last sale price of a share of the Company’s common stock reported for the Business Day immediately before
      the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company multiplied by the number of shares of the Company’s common stock into which a Share is then convertible. If the Company’s common stock is not traded in
      a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith judgment.

  

  

  1.4          Delivery of Certificate and New Warrant.  Within a reasonable time after Holder exercises this Warrant in the manner set forth in Section 1.1 or 1.2 above,
      the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Shares not so acquired.

  

  

  1.5          Replacement of Warrant.  On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in
      the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the
      Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount.

  

  

  1.6            Treatment of Warrant Upon Acquisition of Company.

  

  

  (a)           Acquisition. For the purpose of this Warrant, “Acquisition”
      means any transaction or series of related transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with
      another person or entity (other than a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such
      merger, consolidation or reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company stockholders
      beneficially own a majority of the outstanding voting power of the surviving or successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii) any sale or other
      transfer by the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power.

  

  

  (b)           Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the Company’s stockholders consists solely
      of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), either (i) Holder
      shall exercise this Warrant pursuant to Section 1.1 and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent upon the consummation of such Acquisition or (ii) if Holder elects not to exercise the Warrant, this Warrant
      will expire immediately prior to the consummation of such Acquisition.

  

  

  (c)           The Company
      shall provide Holder with written notice of its request relating to the Cash/Public Acquisition (together with such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated
      Cash/Public Acquisition giving rise to such notice), which is to be delivered to Holder not less than seven (7) Business Days prior to the closing of the proposed Cash/Public Acquisition. In the event the Company does not provide such notice, then
      if, immediately prior to the Cash/Public Acquisition, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on
      such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall
      promptly notify the Holder of the number of Shares (or such other securities) issued upon such exercise to the Holder and Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as the date
      thereof.

  
    2

    
      
 

  

  (d)           Upon the
      closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or
      other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time
      in accordance with the provisions of this Warrant.

  

  

  (e)            As used in
      this Warrant, “Marketable Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then subject to
      the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is
      then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were
      Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s shares and/or other
      securities that would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such restriction (x) arises solely under federal or
      state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Acquisition.

  

  

  1.7          Adjustment to Class of Shares; Number of Shares; Warrant Price; Adjustments Cumulative. If, upon the closing of the Next Equity Financing, the Next Equity
      Financing Price shall be less than the Warrant Price in effect as of immediately prior thereto, then the “Class” shall be Next Equity Financing Securities from and after such closing, subject to adjustment thereafter from time to time in accordance
      with the provisions of this Warrant and the “Warrant Price” shall be the Next Equity Financing Price from and after such closing, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant; provided, that
      upon such date, if any, as the “Class” becomes Next Equity Financing Securities pursuant to this sentence, this Warrant shall be exercisable for such number of shares of such Class as shall equal (i) [_______] divided by (ii) the Next Equity
      Financing Price, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant. As used herein (i) “Next
        Equity Financing” means the first sale or issuance by the Company on or after the Issue Date of this Warrant set forth above, in a single transaction or series of related transactions, of shares of its convertible preferred stock or other
      senior equity securities to one or more investors for cash for financing purposes; (ii) “Next Equity Financing Securities” means the type,
      class and series of convertible preferred stock or other senior equity security sold or issued by the Company in the Next Equity Financing; and (iii) “Next Equity Financing Price” means the lowest price per share for which Next Equity Financing Securities are sold or issued by the Company in the Next Equity Financing.

  

  

  SECTION 2.       ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

  

  

  2.1            Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Class payable in common stock or
      other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which Holder would have
      received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the number of Shares
      purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number of shares,
      the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.

  
    3

    
      
 

  

  2.2           Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Class are reclassified, exchanged,
      combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and series of Company
      securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant. The provisions
      of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events.

  

  

  2.3           Conversion of Preferred Stock. If the Class is a class and series of the Company’s convertible preferred stock, in the event that all outstanding shares of
      the Class are converted, automatically or by action of the holders thereof, into common stock pursuant to the provisions of the Company’s Certificate of Incorporation, including, without limitation, in connection with the Company’s initial,
      underwritten public offering and sale of its common stock pursuant to an effective registration statement under the Act (the “IPO”), then
      from and after the date on which all outstanding shares of the Class have been so converted, this Warrant shall be exercisable for such number of shares of common stock into which the Shares would have been converted had the Shares been outstanding
      on the date of such conversion, and the Warrant Price shall equal the Warrant Price in effect as of immediately prior to such conversion divided by the number of shares of common stock into which one Share would have been converted, all subject to
      further adjustment thereafter from time to time in accordance with the provisions of this Warrant.

  

  

  2.4           Adjustments for Diluting Issuances. Without duplication of any adjustment otherwise provided for in this Section 2, the number of shares of common stock
      issuable upon conversion of the Shares shall be subject to anti-dilution adjustment from time to time in the manner set forth in the Company’s Articles or Certificate of Incorporation as if the Shares were issued and outstanding on and as of the date
      of any such required adjustment.

  

  

  2.5           No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued shall be rounded down to the
      nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional interest by (i) the
      fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price.

  

  

  2.6          Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company, at the Company’s expense, shall
      notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from Holder, furnish Holder
      with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such adjustment.

  

  

  SECTION 3.        REPRESENTATIONS AND COVENANTS OF THE COMPANY.

  

  

  3.1            Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:

  

  

  (a)           The initial
      Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares of the Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least $500,000 of such
      shares were sold.

  

  

  (b)            All Shares
      which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances
      except for restrictions on transfer provided for herein or under applicable federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock
      such number of shares of the Class, common stock and other securities as will be sufficient to permit the exercise in full of this Warrant and the conversion of the Shares into common stock or such other securities.

  

  
    4

    
      
 

  

  
    (c)            The
        Company’s capitalization table provided to Holder on the date hereof is true and complete, in all material respects, as of the Issue Date.

    

    

    3.2            Notice of Certain Events. If the Company proposes at any time to:

    

    

    (a)             declare
        any dividend or distribution upon the outstanding shares of the Class or common stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend;

    

    

    (b)          offer for
        subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights);

     

      

    (c)             effect any
        reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the Class;

    
      

      

      
        (d)             effect an Acquisition or to liquidate,
            dissolve or wind up; or

         

          

        
          (e)             effect an IPO;

           

      

       

  

    
  

  

  then, in connection with each such event, the Company shall give Holder:

  

  

  (1)          at least
      seven (7) Business Days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled
      thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above;

  

  

  (2)          in the case
      of the matters referred to in (c) and (d) above at least seven (7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to
      exchange their shares for the securities or other property deliverable upon the occurrence of such event); and

  

  

  (3)          with respect
      to the IPO, at least seven (7) Business Days prior written notice of the date on which the Company proposes to file its registration statement in connection therewith.

   

    

  Reference is made to Section 1.6(c) whereby this Warrant will be deemed to be exercised pursuant to Section 1.2 hereof if the Company does not give written
    notice to Holder of a Cash/Public Acquisition as required by the terms hereof. Company will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements.

  

  

  SECTION 4.       REPRESENTATIONS, WARRANTIES OF THE HOLDER.

  

  

  The Holder represents and warrants to the Company as follows:

  

  

  4.1            Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being acquired for investment for
      Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant or the Shares.

  

  

  4.2            Disclosure of Information.   Holder is aware of the Company’s business affairs and financial condition and has received or has had full access to all the
      information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from
      the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or
      expense) necessary to verify any information furnished to Holder or to which Holder has access.

  
    5

    
      
 

  

  4.3            Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk. Holder has experience
      as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience in financial or
      business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its officers,
      directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons.

  

  

  4.4            Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.

  

  

  4.5          The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the Act in reliance upon a
      specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof must be
      held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144
      promulgated under the Act.

  

  

  4.6          Market Stand-off Agreement. If requested by the Company or an underwriter, Holder shall not sell or otherwise transfer, make any short sale of, grant any
      option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale of, any shares of the Company’s capital stock held by Holder (other than those included in the registration) during for such period
      of time as reasonably requested by the Company or such underwriter, but not to exceed the 180-day period following the effective date of a registration statement of the Company filed under the Securities Act of 1933, as amended (the “Lock Up Period”). Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company and/or the managing
      underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the shares of capital stock of
      the Company held by Holder until the end of such period. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 4.6 and shall have the right, power and authority to enforce the provisions hereof as though they
      were a party hereto. Notwithstanding the foregoing, Holder shall only be subject to the foregoing provisions of this Section 4.6 so long as each of the Company’s other stockholders that hold at least 1% of the outstanding voting securities of the
      Company are subject to substantially the same requirements and restrictions.

  4.7            No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant. 

   

    

  
    

    

    SECTION 5.     MISCELLANEOUS.

  

    

  
  
    5.1           Term; Automatic Cashless Exercise Upon Expiration.

     

  

  

  

  

  

  (a)           Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from time to time on or before 6:00
      PM, Pacific time, on the Expiration Date and shall be void thereafter.

  

  

  (b)          Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other security issuable
      upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2
      above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such
      exercise to Holder.

  
    6

    
      
 

  

  5.2           Legends. Each certificate evidencing Shares (and each certificate evidencing the securities issued upon conversion of any Shares, if any) shall be imprinted
      with a legend in substantially the following form:

  

  

  THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO [__________] DATED
    [______________], MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER
    TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

  

  

  5.3            Compliance with Securities Laws on Transfer. This Warrant and the Shares issued upon exercise of this Warrant (and the securities issuable, directly or
      indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the
      delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to [an]
      [[__________] ([__________] parent company) or any other] affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an
      opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act.

  

  

  5.4          Transfer Procedure. After receipt by [__________] of the executed Warrant, [__________]  [may][will] transfer all [or part] of this Warrant to [its
      parent company, [__________]] [one or more of [__________]’s affiliates (each, an “[__________] Affiliate”), by execution of an Assignment
      substantially in the form of Appendix 2]. [By its acceptance of this Warrant, [__________] hereby makes to the Company each of the representations and warranties set forth in Section 4 hereof and agrees to be bound by all of the terms and conditions
        of this Warrant as if the original Holder hereof.] Subject to the provisions of [Article][Section] 5.3 and upon
        providing the Company with written notice, [__________] [[__________], any such [__________] Affiliate] and any
        subsequent Holder, may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the
      [securities] [Shares]  issuable directly or indirectly, upon conversion of the Shares, if any) to any [other] transferee,
        provided, however, in connection with any such transfer, [__________] [the [__________] Affiliate(s)] or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and
        taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable); [and provided further, that any subsequent transferee other than [__________] shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant]. Notwithstanding any contrary provision herein, at all times prior to the IPO, Holder may not, without the
        Company’s prior written consent, transfer this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, or any shares or other securities issued upon any conversion of any Shares issued upon any exercise hereof, to any person
        or entity who directly competes with the Company, except in connection with an Acquisition of the Company by such a direct competitor.

  
    7

    
      
 

  

  5.5          Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered and effective (i) when
      given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed in writing by the
      recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the
      Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company
      receives notice of a change of address in connection with a transfer or otherwise:

            

  

  

  [_______________________

  Attn: __________________

  _______________________

    Telephone:______________

    Facsimile:_______________

    Email:__________________]

  

  

  Notice to the Company shall be addressed as follows until Holder receives notice of a change in address:

  

  

  Castle Biosciences, Inc.

      820 S. Friendswood Drive, Suite 201

      Friendswood, Texas 77546

      Attn: James L. Dunn, Jr.

      

  

  With a copy (which shall not constitute notice) to:

  

  

  Cooley LLP

    101 California Street, 5th Floor

    San Francisco, California 94111

    Attn: Maricel Mojares-Moore

    Telephone: 

    Facsimile: 

    Email: 

  

  

  

  5.6           Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular instance and either
      retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought.

  

  

  5.7           Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute
      shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.

  

  

  5.8        Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall constitute one and the same
      agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.

  

  

  5.9            Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without giving effect to its
      principles regarding conflicts of law.

  

  

  5.10          Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of this
      Warrant.

  

  

  5.11          Business Days. “Business Day” is any day that
      is not a Saturday, Sunday or a day on which [________________] is closed.

  
    8

    
      
 

  

  [Remainder of page left blank intentionally]

  

  

  [Signature page follows]

  
    9

    
      
 

  

  IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives effective
    as of the Issue Date written above.

  

  

  	
          “COMPANY”

        	 
	 	 	 
	
          CASTLE BIOSCIENCES, INC.

        	 
	 	 	 
	
          By:

        	 	 
	 	 	 
	
          Name:

        	 	 
	 	
          (Print)

        	 
	
          Title:

        	 	 

  

  

  	
          “HOLDER”

        	 
	 	 	 
	
          [________________]

        	 
	 	 	 
	
          By:

        	 	 
	 	 	 
	
          Name:

        	 	 
	 	
          (Print)

        	 
	
          Title:

        	 	 

  

  

  [Signature Page to Warrant to Purchase Stock]

  

  
    
      
 

  

  
  APPENDIX 1

  

  

  NOTICE OF EXERCISE

  

    

  1.          The undersigned
      Holder hereby exercises its right purchase __________________ shares of the Common/Series ______ Preferred [circle one] Stock of CASTLE BIOSCIENCES, INC. (the “Company”) in accordance with the attached Warrant To Purchase Stock, and tenders payment of the aggregate Warrant Price for such shares as follows:

  

  

  
    	
            

            

          	
            [   ]

          	
            check in the amount of $________ payable to order of the Company enclosed herewith

          

  

  
    

    

    
      	 	
              [   ]

            	
              Wire transfer of immediately available funds to the Company’s account

            

    

  

  
    

    

    
      	 	
              [   ]

            	
              Cashless Exercise pursuant to Section 1.2 of the Warrant

            

    

  

  
    

    

    
      	 	
              [   ]

            	
              Other [Describe] __________________________________________

            

    

  

  

  

  2.             Please issue a certificate
      or certificates representing the Shares in the name specified below:

  	 	 	 
	 	
          Holder’s Name

        	 
	 	 	 
	 	 	 
	 	 	 
	 	
          (Address)

        	 

  

  

  3.              By its
      execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof.

  

  

  	 	
          HOLDER:

        
	 	 	 	 
	 	 	 	 
	 	
          By:

        	 	 
	 	 	 	 
	 	
          Name:

        	 
	 	 	 	 
	 	
          Title:

        	 
	 	 	 	 
	 	
          Date:

        	 

  
    Appendix 2

    
      
 

  

  
  [APPENDIX 2]

  

    

  ASSIGNMENT

  

    

  For value received, [________________] hereby sells, assigns and transfers unto

  

  

  	 	
          Name:

        	
          [[______] TRANSFEREE]

        	 
	 	 	 	 
	 	
          Address:

        	 	 
	 	 	 	 
	 	
          Tax ID:

        	 	
          ]

        

  

  

  that certain Warrant to Purchase Stock issued by CASTLE BIOSCIENCES, INC. (the “Company”), on [_____________] (the “Warrant”) together with all rights, title and interest therein.

  

  

  	 	 	 	 
	 	
          [_____________]

        
	 	 	 	 
	 	
          By:

        	 	 
	 	 	 	 
	 	
          Name:

        	 
	 	 	 	 
	 	
          Title:

        	 

  

  

  	
          Date:

        	 	 

  

  

  By its execution below, and for the benefit of the Company, [[______] TRANSFEREE] makes each of the representations and warranties set forth in Article 4 of
    the Warrant and agrees to all other provisions of the Warrant as of the date hereof.

  

  

  	 	 	 	 
	 	
          [[______] TRANSFEREE]

        
	 	 	 	 
	 	
          By:

        	 	 
	 	 	 	 
	 	
          Name:

        	 
	 	 	 	 
	 	
          Title:

        	 

   

  
    Appendix 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]